로고

  • HOME
  • SITEMAP
  • kOREAN
Home > Company Profile > CEO Message

We, Seoul Pharma Co. Ltd, have researched, developed, manufactured and marketed the qualified medicines to save
people’s lives since its foundation in 1976. We have actively invested on the R&D for new medicines since the mid-2000s,
especially for anti-cancer drugs and phytomedicine. With our dedication, we have launched many competitive products
and engaged R&D in state-of-the-art fields such as biotechnology. We think our annual sales growth of 27% CAGR for
last 5 years reflects on our sense of duty to develop new medicines through such R&D investment.

In the aspect of R&D investment for new and incrementally modified drugs, we have already succeeded in launching
the sustained-release products for hyperlipidemia, fever and pain through our own DDS technology. Recently, we have
carried out preclinical and clinical studies of new medicines such as SPX-601, extract-based candidate for arthritis and
SPC-701, candidate for sepsis. Eventually, we will continue striving to develop new medicines targeting global market.

Particularly, our SmartFilm® technology, which is a DDS technology to produce Orally Disintegrating Film (ODF), results
from our effort and devotion to develop the new technology under our confidence since 2009 that our future depends on
how to secure platform technology and strengthen core competence.

The SmartFilm® technology is differentiated from the existing platform one, because it is the globally leading technology to
enable to load the higher dose of active pharmaceutical ingredients, secure the optimal manufacturing process of ODF
and mask the bitter taste of medicines.

In May 2012, we launched “Vultis®” 100mg and 50mg (sildenafil citrate) in Korea for the treatment of erectile dysfunction
and it is evaluated as the first ODF product with SmartFilm® technology in the world. For the global and Korean markets,
we have already completed manufacturing facilities in Sihwa plant with GMP standards.

Now, we prepared the pipeline with SmartFilm® technology as the next products to Vultis® and are going launch new
products in some therapeutic categories of CNS, pediatrics and geriatrics to improve the quality of life. Also, we will
consolidate the global network to enter into the regulated markets and jump up to become a global company.
To approach our goal, we are constructing new cGMP standard plant at Osong city, Chungnam province on a scale of
total ground of 33,000㎡ and 8,500㎡ floor space. Its facilities in current construction are also designed in terms of
environmental perspective.

Taking the new cGMP plant construction at Osong city, we prepared pipeline to launch new products based on
continuous investment on R&D, platform technology of SmartFilm®. Furthermore, we will position our company in the
global pharmaceutical industry by entering into global market.

We appreciate you for your continuous support and encouragement to us until our company becomes one of the global
leading pharmaceutical companies through SmartFilm® technology.